Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Bornemann-Cimenti, H; Wejbora, M; Szilagyi, IS; Sandner-Kiesling, A.
Fentanyl for the treatment of tumor-related breakthrough pain.
Dtsch Arztebl Int. 2013; 110(16):271-277
Doi: 10.3238/arztebl.2013.0271
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Bornemann-Cimenti Helmar
- Sandner-Kiesling Andreas
- Co-Autor*innen der Med Uni Graz
- Szilagyi Istvan - Szilard
- Wejbora Mischa
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life. The treatment for BTCP episodes that is recommended in current guidelines involves extended-release formulations in combination with rapid-onset and short-acting opioids. In the past few years, several new preparations of fentanyl, an opioid with a very rapid onset, have been approved for this indication. Treating physicians need to be aware of the clinical differences between the newer fentanyl preparations and immediate-release opioids. Methods: We searched the PubMed and Embase databases for randomized controlled trials (RCTs) of fentanyl for buccal, sublingual or intranasal administration in comparison with other opioids or a different fentanyl preparation for the treatment of BTCP. Results: In 6 trials of buccal, sublingual or intranasal fentanyl versus oral immediate-release opioids for the treatment of BTCP episodes, the use of fentanyl was associated with significantly less intense pain. In particular, fentanyl more often lowered the intensity of pain by at least 33% (range between studies: 13% to 57%) or by at least 50% (range between studies: 9% to 38%) within 15 minutes. Please change to "versus" if you agree.] Dose titration should begin at the lowest dose. When one fentanyl preparation is exchanged for another, the effective dose will probably differ. Conclusion: The newer fentanyl preparations extend the treatment options for BTCP. They relieve pain within a short time better than conventional, immediate-release oral opioids do and may therefore be very helpful for patients with suddenly arising, intense, and short-lasting BTCP episodes. Further comparative trials are urgently needed.
- Find related publications in this database (using NLM MeSH Indexing)
- Analgesics, Opioid - adverse effects Analgesics, Opioid - therapeutic use
- Breakthrough Pain - diagnosis Breakthrough Pain - drug therapy Breakthrough Pain - etiology
- Evidence-Based Medicine -
- Fentanyl - adverse effects Fentanyl - therapeutic use
- Humans -
- Neoplasms - complications Neoplasms - nursing
- Pain Measurement - drug effects
- Treatment Outcome -